Clinipol Holdings Ltd 09230340 false 2022-04-01 2023-03-31 2023-03-31 The principal activity of the company is that of a holding company. Digita Accounts Production Advanced 6.30.9574.0 true false false false false 09230340 2022-04-01 2023-03-31 09230340 2023-03-31 09230340 bus:OrdinaryShareClass1 bus:CumulativeNon-redeemableShares 2023-03-31 09230340 bus:OrdinaryShareClass2 bus:CumulativeNon-redeemableShares 2023-03-31 09230340 core:CurrentFinancialInstruments 2023-03-31 09230340 core:CurrentFinancialInstruments core:WithinOneYear 2023-03-31 09230340 core:CostValuation 2023-03-31 09230340 bus:SmallEntities 2022-04-01 2023-03-31 09230340 bus:AuditExemptWithAccountantsReport 2022-04-01 2023-03-31 09230340 bus:FullAccounts 2022-04-01 2023-03-31 09230340 bus:SmallCompaniesRegimeForAccounts 2022-04-01 2023-03-31 09230340 bus:RegisteredOffice 2022-04-01 2023-03-31 09230340 bus:Director1 2022-04-01 2023-03-31 09230340 bus:Director2 2022-04-01 2023-03-31 09230340 bus:Director3 2022-04-01 2023-03-31 09230340 bus:Director4 2022-04-01 2023-03-31 09230340 bus:Director5 2022-04-01 2023-03-31 09230340 bus:OrdinaryShareClass1 bus:CumulativeNon-redeemableShares 2022-04-01 2023-03-31 09230340 bus:OrdinaryShareClass2 bus:CumulativeNon-redeemableShares 2022-04-01 2023-03-31 09230340 bus:PrivateLimitedCompanyLtd 2022-04-01 2023-03-31 09230340 core:Subsidiary1 2022-04-01 2023-03-31 09230340 core:Subsidiary1 1 2022-04-01 2023-03-31 09230340 core:Subsidiary1 countries:AllCountries 2022-04-01 2023-03-31 09230340 core:Subsidiary2 2022-04-01 2023-03-31 09230340 core:Subsidiary2 1 2022-04-01 2023-03-31 09230340 core:Subsidiary2 countries:AllCountries 2022-04-01 2023-03-31 09230340 core:Subsidiary3 2022-04-01 2023-03-31 09230340 core:Subsidiary3 1 2022-04-01 2023-03-31 09230340 core:Subsidiary3 countries:AllCountries 2022-04-01 2023-03-31 09230340 countries:EnglandWales 2022-04-01 2023-03-31 09230340 core:CostValuation 2022-03-31 09230340 2021-04-01 2022-03-31 09230340 2022-03-31 09230340 bus:OrdinaryShareClass1 bus:CumulativeNon-redeemableShares 2022-03-31 09230340 bus:OrdinaryShareClass2 bus:CumulativeNon-redeemableShares 2022-03-31 09230340 core:CurrentFinancialInstruments 2022-03-31 09230340 core:CurrentFinancialInstruments core:WithinOneYear 2022-03-31 09230340 core:Subsidiary1 1 2021-04-01 2022-03-31 09230340 core:Subsidiary2 1 2021-04-01 2022-03-31 09230340 core:Subsidiary3 1 2021-04-01 2022-03-31 iso4217:GBP xbrli:pure xbrli:shares

Registration number: 09230340

Clinipol Holdings Ltd

Annual Report and Unaudited Financial Statements

for the Year Ended 31 March 2023

 

Clinipol Holdings Ltd

Contents

Company Information

1

Balance Sheet

2 to 3

Notes to the Unaudited Financial Statements

4 to 8

 

Clinipol Holdings Ltd

Company Information

Directors

M. Lord

A. P. Hooley

A. Holmes

D. M. McClellan

G. Shaw

Registered office

Unit 3 Garden Court
Gee Road
Whitwick Business Park
Coalville
Leicestershire
LE67 4NB

Accountants

Robert Whowell & Partners LLP
Chartered Accountants
Westwood House
78 Loughborough Road
Quorn
Loughborough
Leicestershire
LE12 8DX

 

Clinipol Holdings Ltd

(Registration number: 09230340)
Balance Sheet as at 31 March 2023

Note

2023
£

2022
£

Fixed assets

 

Investments

4

2,199,101

2,199,101

Current assets

 

Debtors

5

1,800

124,300

Cash at bank and in hand

 

375,000

450,000

 

376,800

574,300

Creditors: Amounts falling due within one year

6

(677,601)

(1,172,601)

Net current liabilities

 

(300,801)

(598,301)

Net assets

 

1,898,300

1,600,800

Capital and reserves

 

Called up share capital

7

600

600

Share premium reserve

1,200

1,600,200

Retained earnings

1,896,500

-

Shareholders' funds

 

1,898,300

1,600,800

For the financial year ending 31 March 2023 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

 

Clinipol Holdings Ltd

(Registration number: 09230340)
Balance Sheet as at 31 March 2023

Directors' responsibilities:

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

These financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the directors have not delivered to the registrar a copy of the Profit and Loss Account.

Approved and authorised by the Board on 19 October 2023 and signed on its behalf by:
 

.........................................
A. Holmes
Director

 

Clinipol Holdings Ltd

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2023

1

General information

The company is a private company limited by share capital, incorporated in England and Wales.

The address of its registered office is:
Unit 3 Garden Court
Gee Road
Whitwick Business Park
Coalville
Leicestershire
LE67 4NB

These financial statements were authorised for issue by the Board on 19 October 2023.

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Business combinations

Business combinations are accounted for using the purchase method. The consideration for each acquisition is measured at the aggregate of the fair values at acquisition date of assets given, liabilities incurred or assumed, and equity instruments issued by the group in exchange for control of the acquired, plus any costs directly attributable to the business combination. When a business combination agreement provides for an adjustment to the cost of the combination contingent on future events, the group includes the estimated amount of that adjustment in the cost of the combination at the acquisition date if the adjustment is probable and can be measured reliably.

 

Clinipol Holdings Ltd

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2023

Investments

Investments in equity shares which are publicly traded or where the fair value can be measured reliably are initially measured at fair value, with changes in fair value recognised in profit and loss account. Investments in equity shares which are not publicly traded and where fair value cannot be measured reliably are measured at cost less impairment.

Interest income on debt securities, where applicable, is recognised in income using the effective interest method. Dividends on equity securities are recognised in income when receivable.

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

Dividends

Dividend distribution to the company’s shareholders is recognised as a liability in the financial statements in the reporting period in which the dividends are declared.

Share based payments

Equity-settled share-based payments are measured at fair value at the date of grant by reference to the fair value of the equity instruments granted. The fair value determined at the grant date is expensed on a straight-line basis over the vesting period, based on the estimate of shares that will eventually vest. A corresponding adjustment is made to equity.

3

Staff numbers

The average number of persons employed by the company (including directors) during the year, was 5 (2022 - 5).

4

Investments

2023
£

2022
£

Investments in subsidiaries

2,199,101

2,199,101

 

Clinipol Holdings Ltd

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2023

Subsidiaries

£

Cost or valuation

At 1 April 2022

2,199,101

At 31 March 2023

2,199,101

Carrying amount

At 31 March 2023

2,199,101

At 31 March 2022

2,199,101

 

Clinipol Holdings Ltd

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2023

Details of undertakings

Details of the investments (including principal place of business of unincorporated entities) in which the company holds 20% or more of the nominal value of any class of share capital are as follows:

Undertaking

Registered office

Holding

Proportion of voting rights and shares held

     

2023

2022

Subsidiary undertakings

Clinical Polymer Technologies Ltd

Unit 3, Garden Court, Gee Road, Coalville, Leicestershire, LE67 4NB

England & Wales

Ordinary

100%

100%

Mowtec Limited

Unit 3, Garden Court, Gee Road, Coalville, Leicestershire, LE67 4NB

England & Wales

Ordinary

100%

100%

Mowtec Device Innovations (Medic) Ltd

Unit 3, Garden Court, Gee Road, Coalville, Leicestershire, LE67 4NB

England & Wales

Ordinary

100%

100%

Subsidiary undertakings

Clinical Polymer Technologies Ltd

The principal activity of Clinical Polymer Technologies Ltd is the manufacture of rubber products.

Mowtec Limited

The principal activity of Mowtec Limited is the manufacture of rubber products.

Mowtec Device Innovations (Medic) Ltd

The principal activity of Mowtec Device Innovations (Medic) Ltd is a dormant company.

 

Clinipol Holdings Ltd

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2023

5

Debtors

Current

2023
£

2022
£

Other debtors

1,800

124,300

6

Creditors

Creditors: amounts falling due within one year

Note

2023
£

2022
£

Due within one year

 

Amounts owed to group undertakings

8

677,601

1,172,601

7

Share capital

Allotted, called up and fully paid shares

 

2023

2022

 

No.

£

No.

£

Ordinary shares of £1 each

420

420

420

420

Founder shares of £1 each

180

180

180

180

 

600

600

600

600

8

Related party transactions

The company has taken advantage of the exemption conferred by FRS 102 Section 1A Appexndix C.34-36 not to disclose transactions with other group entities whose voting rights are 100% controlled within the group.

During the year the directors received dividends amounting to £101,300 (2022 - £75,000).